February 13, 2019
FDA warns of link between breast implants and anaplastic large cell lymphoma
Editor's Note
The Food and Drug Administration (FDA) on February 6 posted a letter that was sent to healthcare providers to increase their awareness of the association between all breast implants, regardless of filling or texture, and breast implant associated-anaplastic large cell lymphoma (BIA-ALCL).
As of September 30, 2018, the FDA has received 660 medical device reports of patients who have developed BIA-ALCL, generally within the scar capsule adjacent to the implant.
Free Daily News
- Health systems lean toward established partners for AI adoption
- Immigration raids are driving patients back to telehealth and ERs
- Study: Global access to surgery deemed a crisis, leaves 160 million without care
- Large-scale studies link preoperative cognition to delirium risk, reveal its deadly toll after surgery
- Socioeconomic deprivation linked to lower fitness before surgery, UK study finds
- Perioperative medication decisions need individualized risk-benefit approach
- FDA: National IV saline shortage over after years of strained supply
- FDA announces Class 1 recall for Draeger breathing filters
- Hospital CEO departures surge, boards turn to interim leadership
- Study: Attire shapes patient trust, perceptions
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement